Physician profile
Doris Lippman
NPI 1538600051
$3,217.52
in general payments reported to CMS, 2019-2025
14 companies · $429 in 2025
The $429 reported for 2025 was more than what 83% of Psychiatric/Mental Health, Adult (Registered Nurse) providers received nationally (typical 2025 total: $121).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $543 · 2022: $622 · 2023: $954 · 2024: $669 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,052.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,226.86 | 2022-2025 | Caplyta |
| Abbvie INC. | $983.34 | 2021-2024 | |
| Glaxosmithkline, LLC. | $228.71 | 2021-2023 | Benlysta |
| Neurocrine Biosciences, INC. | $137.50 | 2024 | Ingrezza |
| Corium, LLC | $111.24 | 2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $110.58 | 2022-2023 | Qelbree |
| Ucb, INC. | $109.89 | 2023 | Cimzia |
| Vanda Pharmaceuticals INC. | $83.76 | 2025 | Fanapt |
| Mallinckrodt Hospital Products INC. | $75.40 | 2021-2023 | Acthar |
| Almatica Pharma LLC | $53.06 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.31 | 2022 | |
| Janssen Biotech, INC. | $24.62 | 2023 | Tremfya |
| Adlon Therapeutics L.P. | $24.20 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $23.05 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Lippman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.